Thursday, August 27, 2026

The Evolution of Pharmaceutical Industry CPD/CME Support: A 50-Year Retrospective

By: Kate Biles, CHCP

Continuing professional development/continuing medical education (CPD/CME) has developed significantly over time. For centuries, physicians entered the field by apprenticing with experienced practitioners or earning a degree from a university. But once they began treating patients and encountered new, more complex challenges, it became clear that formal training was only the starting point. Physicians recognized that practicing medicine required ongoing learning — a continual effort to update their skills and knowledge. This realization marked the beginning of a long‑term commitment to CPD/CME.^1,2

CPD and CME have since been cornerstones of professional development for healthcare providers, ensuring that clinicians remain current with emerging medical knowledge, technologies and best practices, ultimately leading to better patient outcomes.^1-3 Over the past five decades, the pharmaceutical industry's role in supporting CPD/CME has undergone significant transformation — shaped by evolving regulatory landscapes, ethical considerations, technological advancements and shifting educational paradigms. This article explores the historical trajectory, key milestones and future directions of pharmaceutical industry support for CPD/CME.

The Origins: Informal Beginnings and Early Sponsorship (1970s-1980s)

In the 1970s, CPD/CME was largely informal, often consisting of lectures and conferences organized by hospitals or medical societies. Pharmaceutical companies began sponsoring these events to disseminate information about new therapies and build relationships with healthcare professionals. While these efforts were well-intentioned, they were often criticized for being promotional in nature, lacking transparency and potentially influencing prescribing behavior. The teams that led CPD/CME support at pharmaceutical companies were usually involved in marketing, unlike today’s medical education teams, which are completely independent from commercial involvement.

During this period, there were few formal guidelines governing industry involvement in CME. The American Medical Association (AMA) and other professional bodies began to recognize the need for clearer boundaries, leading to early discussions about ethical standards and the separation of education from marketing.

Formalization and Accreditation: The Rise of Standards (1990s)

The 1990s marked a turning point with the establishment of the Accreditation Council for Continuing Medical Education (ACCME) as a central body to accredit CME providers and enforce standards. ACCME introduced criteria to ensure that CME activities were independent, evidence-based and free from commercial bias.⁴

Pharmaceutical companies responded by creating dedicated medical education departments and grant offices to manage CME funding in compliance with these standards. The industry began to distinguish between promotional activities and independent educational grants, with the latter requiring strict firewalls between content development and commercial interests.

Regulatory Oversight and Compliance: The Impact of the OIG and PhRMA Code (2000s)

In the early 2000s, the U.S. Office of Inspector General (OIG) issued compliance guidance for pharmaceutical manufacturers, emphasizing the need for transparency and ethical conduct in interactions with healthcare professionals. This was followed by the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals, which set forth voluntary guidelines for industry behavior.⁵

These developments led to a significant reduction in direct sponsorship of CME events and a shift toward funding through independent grant mechanisms. Companies who developed CME activities as well as their supporters implemented rigorous internal policies to ensure compliance, including the use of grant review committees, documentation protocols, and post-activity evaluations, as well as online grant portals separated from other areas of the company.

Outcomes-based Education and Interprofessional Learning (2010s)

As CME evolved from knowledge transfer to performance and quality improvement, the industry adapted its support to align with outcomes-based education.⁶ Grant applications increasingly required needs assessments, learning objectives and metrics to evaluate impact on clinical practice. The Moore’s model became the staple for outcomes evaluation of CME activities, and providers began to develop more detailed outcomes reporting to their supporters.

The rise of interprofessional education — bringing together physicians, pharmacists, nurses and other healthcare professionals — also influenced CME design. Pharmaceutical companies began funding programs that addressed team-based care, patient safety, system constraints and chronic disease management, reflecting broader healthcare trends beyond specific treatments for disease. Pharmaceutical companies also embraced innovations by supporting eCME formats and investing in platforms that enabled asynchronous learning, real-time analytics, and personalized content.

Technology and Innovation: Digital Transformation of CME (2010s-2020s)

The digital revolution transformed CME delivery, with online platforms, webinars, mobile apps, microlearning and virtual simulations becoming mainstream. This shift expanded access to education, especially for providers in the community setting or in remote and underserved areas.

Compliance policies were updated to address new challenges, such as data privacy and virtual engagement.

Transparency, Metrics and Strategic Alignment (2020s-Present)

In recent years, the focus has shifted toward transparency, strategic alignment and measurable impact. Pharmaceutical and medical device companies implemented systems to manage educational grants, track outcomes and ensure compliance with Sunshine Act reporting.⁶

Educational strategy now involves gap analyses, stakeholder engagement and alignment with therapeutic area priorities. Internal CME departments conduct ongoing monitoring of supported initiatives, to ensure scientific accuracy, and balanced and bias-free content.

Internal training programs for medical directors and other stakeholders emphasize the principles of independent medical education, including the prohibition of promotional influence, the importance of reputable providers and the need for rigorous review processes.

Internal grant teams are charged with not only developing annual strategic educational plans, aligned with medical goals, but also significant involvement in internal medical team collaboration and insight sharing.

Challenges and Future Directions

Despite progress, challenges in CPD/CME remain. These include:

Balancing educational value with compliance: Ensuring that CME remains unbiased while addressing real-world clinical needs.
Navigating global regulations: Different countries have varying standards for CME and industry involvement.
Measuring impact: Developing robust metrics to assess changes in clinician behavior and improved patient outcomes.
Engaging underserved populations: Expanding CME access to rural and minority providers to reduce disparities in care.

Looking ahead, the industry is likely to continue supporting CME through strategic partnerships, data-driven planning and a commitment to ethical standards. The integration of artificial intelligence, personalized learning, and real-world evidence will further enhance the relevance and effectiveness of CME.

Advancing CPD/CME as a Supporter

Over the past 23 years I have spent as a supporter of CPD/CME from the pharmaceutical industry, I have seen such change, evolution and advancement in how education is designed, delivered and measured. We have made so much progress, but there is always more work to be done to advance CPD/CME. With the advent of AI, change is happening at a rapid pace. With all of the advances, CPD/CME has gone through, our primary focus is still improving HCP competence, confidence and performance in the effort to improve patient outcomes. We should always remember the patient is at the core of what we do, every day.

AI Disclaimer: The author used the assistance of CoPilot in developing this article. The points are those of the author.